A199730 Stock Overview
Bioinfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioInfra Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩10,240.00 |
| 52 Week High | ₩24,200.00 |
| 52 Week Low | ₩9,910.00 |
| Beta | 0 |
| 1 Month Change | -9.30% |
| 3 Month Change | -7.75% |
| 1 Year Change | -52.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.17% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| A199730 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -2.5% | -0.8% | 2.7% |
| 1Y | -52.3% | 3.6% | 5.8% |
Return vs Industry: A199730 underperformed the KR Life Sciences industry which returned 3.6% over the past year.
Return vs Market: A199730 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
| A199730 volatility | |
|---|---|
| A199730 Average Weekly Movement | 3.4% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A199730 has not had significant price volatility in the past 3 months.
Volatility Over Time: A199730's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | n/a | www.bioinfrakorea.co.kr |
Bioinfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. Its primary product is a bioequivalence test for generic drugs, a phase 1 test for incrementally modified drugs; and a phase 1 sample analysis for other new substances. The company was founded in 2007 and is based in Yongin-si, South Korea.
BioInfra Co., Ltd. Fundamentals Summary
| A199730 fundamental statistics | |
|---|---|
| Market cap | ₩49.12b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A199730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A199730 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A199730 perform over the long term?
See historical performance and comparison